Clinical decision on a patient with ALK+diffuse large B cell lymphoma / 中国肿瘤临床
Ling DONG; Bin MENG; Xinwei ZHANG; Xiuyu SONG; Ximei ZHANG; Qiongli ZHAI; Xia LIU; Yun HOU; Wei LI; Xianhuo WANG; Huaqing WANG; Kai FU; Huilai ZHANG.
Chinese Journal of Clinical Oncology
; (24): 385-391, 2016.
Artículo
en Zh
| WPRIM | ID: wpr-494347
Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regi-men is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This arti-cle presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibi-tor Crizotinib.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados